Clinical Trial Update: Camrelizumab, Apatinib and Nab-paclitaxel as Second-line Treatment in Advanced Gastric Cancer [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update on camrelizumab, apatinib, and nab-paclitaxel as second-line treatment for advanced gastric cancer in Phase 1/2.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer

Drugs mentioned

• Apatinib (apatinib)
• Camrelizumab (camrelizumab)
• Nab-paclitaxel (paclitaxel protein-bound)

Snippet

Sponsor: Chinese PLA General Hospital | Conditions: Advanced Gastric Cancer | Phase 1, Phase 2 | Status: UNKNOWN